- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
According to our latest study, the global Pharmacogenomics Technology (Theranostics & CDx) market size was valued at USD 9869.6 million in 2022 and is forecast to a readjusted size of USD 24800 million by 2029 with a CAGR of 14.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Pharmacogenomics Technology (Theranostics & CDx) manufacturers include Illumina, Roche and Agilent etc. The top 3 company holds a share of more than 50%. North America takes up the largest sales market, with a share of more than 40%, followed by Europe and China, with the share of about 30% and 10% respectively.
This report is a detailed and comprehensive analysis for global Pharmacogenomics Technology (Theranostics & CDx) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Pharmacogenomics Technology (Theranostics & CDx) market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pharmacogenomics Technology (Theranostics & CDx)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pharmacogenomics Technology (Theranostics & CDx) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Illumina, Roche, Agilent, Abbott and Thermofisher, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Pharmacogenomics Technology (Theranostics & CDx) market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Instrument
Reagents and Consumables
Others
Market segment by Application
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others
Market segment by players, this report covers
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pharmacogenomics Technology (Theranostics & CDx) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pharmacogenomics Technology (Theranostics & CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology (Theranostics & CDx) from 2018 to 2023.
Chapter 3, the Pharmacogenomics Technology (Theranostics & CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Pharmacogenomics Technology (Theranostics & CDx) market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmacogenomics Technology (Theranostics & CDx).
Chapter 13, to describe Pharmacogenomics Technology (Theranostics & CDx) research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Pharmacogenomics Technology (Theranostics & CDx)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Pharmacogenomics Technology (Theranostics & CDx) by Type
1.3.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type in 2022
1.3.3 Instrument
1.3.4 Reagents and Consumables
1.3.5 Others
1.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market by Application
1.4.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Tumor
1.4.3 Diabetes
1.4.4 Mental Diseases
1.4.5 Cardiovascular Diseases
1.4.6 Others
1.5 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size & Forecast
1.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast by Region
1.6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region, (2018-2029)
1.6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2018-2029)
1.6.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2018-2029)
1.6.6 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business
2.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Illumina Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.2.4 Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Roche Recent Developments and Future Plans
2.3 Agilent
2.3.1 Agilent Details
2.3.2 Agilent Major Business
2.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Agilent Recent Developments and Future Plans
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Abbott Recent Developments and Future Plans
2.5 Thermofisher
2.5.1 Thermofisher Details
2.5.2 Thermofisher Major Business
2.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.5.4 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Thermofisher Recent Developments and Future Plans
2.6 Qiagen
2.6.1 Qiagen Details
2.6.2 Qiagen Major Business
2.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Qiagen Recent Developments and Future Plans
2.7 Guardant Health
2.7.1 Guardant Health Details
2.7.2 Guardant Health Major Business
2.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Guardant Health Recent Developments and Future Plans
2.8 MGI Tech Co., Ltd.
2.8.1 MGI Tech Co., Ltd. Details
2.8.2 MGI Tech Co., Ltd. Major Business
2.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.8.4 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 MGI Tech Co., Ltd. Recent Developments and Future Plans
2.9 Amoydx Biology
2.9.1 Amoydx Biology Details
2.9.2 Amoydx Biology Major Business
2.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.9.4 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Amoydx Biology Recent Developments and Future Plans
2.10 Genomics
2.10.1 Genomics Details
2.10.2 Genomics Major Business
2.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
2.10.4 Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Genomics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Pharmacogenomics Technology (Theranostics & CDx) by Company Revenue
3.2.2 Top 3 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share in 2022
3.2.3 Top 6 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share in 2022
3.3 Pharmacogenomics Technology (Theranostics & CDx) Market: Overall Company Footprint Analysis
3.3.1 Pharmacogenomics Technology (Theranostics & CDx) Market: Region Footprint
3.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market: Company Product Type Footprint
3.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value and Market Share by Type (2018-2023)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2023)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Application (2024-2029)
6 North America
6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2029)
6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2029)
6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2029)
6.3.2 United States Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
6.3.3 Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
6.3.4 Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2029)
7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2029)
7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
7.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2029)
7.3.2 Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
7.3.3 France Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
7.3.5 Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
7.3.6 Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region
8.3.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Region (2018-2029)
8.3.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8.3.3 Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8.3.4 South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8.3.5 India Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
8.3.7 Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
9 South America
9.1 South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2029)
9.2 South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2029)
9.3 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
9.3.1 South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2029)
9.3.2 Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
9.3.3 Argentina Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
10.3.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2029)
10.3.2 Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
10.3.4 UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
11.2 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
11.3 Pharmacogenomics Technology (Theranostics & CDx) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Chain
12.2 Pharmacogenomics Technology (Theranostics & CDx) Upstream Analysis
12.3 Pharmacogenomics Technology (Theranostics & CDx) Midstream Analysis
12.4 Pharmacogenomics Technology (Theranostics & CDx) Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Illumina Company Information, Head Office, and Major Competitors
Table 6. Illumina Major Business
Table 7. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 8. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Illumina Recent Developments and Future Plans
Table 10. Roche Company Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 13. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Roche Recent Developments and Future Plans
Table 15. Agilent Company Information, Head Office, and Major Competitors
Table 16. Agilent Major Business
Table 17. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 18. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Agilent Recent Developments and Future Plans
Table 20. Abbott Company Information, Head Office, and Major Competitors
Table 21. Abbott Major Business
Table 22. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 23. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Abbott Recent Developments and Future Plans
Table 25. Thermofisher Company Information, Head Office, and Major Competitors
Table 26. Thermofisher Major Business
Table 27. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 28. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Thermofisher Recent Developments and Future Plans
Table 30. Qiagen Company Information, Head Office, and Major Competitors
Table 31. Qiagen Major Business
Table 32. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 33. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Qiagen Recent Developments and Future Plans
Table 35. Guardant Health Company Information, Head Office, and Major Competitors
Table 36. Guardant Health Major Business
Table 37. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 38. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Guardant Health Recent Developments and Future Plans
Table 40. MGI Tech Co., Ltd. Company Information, Head Office, and Major Competitors
Table 41. MGI Tech Co., Ltd. Major Business
Table 42. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 43. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. MGI Tech Co., Ltd. Recent Developments and Future Plans
Table 45. Amoydx Biology Company Information, Head Office, and Major Competitors
Table 46. Amoydx Biology Major Business
Table 47. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 48. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Amoydx Biology Recent Developments and Future Plans
Table 50. Genomics Company Information, Head Office, and Major Competitors
Table 51. Genomics Major Business
Table 52. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
Table 53. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Genomics Recent Developments and Future Plans
Table 55. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Players (2018-2023)
Table 56. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players (2018-2023)
Table 57. Breakdown of Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Pharmacogenomics Technology (Theranostics & CDx), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Pharmacogenomics Technology (Theranostics & CDx) Players
Table 60. Pharmacogenomics Technology (Theranostics & CDx) Market: Company Product Type Footprint
Table 61. Pharmacogenomics Technology (Theranostics & CDx) Market: Company Product Application Footprint
Table 62. Pharmacogenomics Technology (Theranostics & CDx) New Market Entrants and Barriers to Market Entry
Table 63. Pharmacogenomics Technology (Theranostics & CDx) Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Share by Type (2018-2023)
Table 66. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Forecast by Type (2024-2029)
Table 67. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023)
Table 68. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Forecast by Application (2024-2029)
Table 69. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Pharmacogenomics Technology (Theranostics & CDx) Raw Material
Table 100. Key Suppliers of Pharmacogenomics Technology (Theranostics & CDx) Raw Materials
List of Figures
Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Picture
Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type in 2022
Figure 4. Instrument
Figure 5. Reagents and Consumables
Figure 6. Others
Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application in 2022
Figure 9. Tumor Picture
Figure 10. Diabetes Picture
Figure 11. Mental Diseases Picture
Figure 12. Cardiovascular Diseases Picture
Figure 13. Others Picture
Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Region in 2022
Figure 19. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players in 2022
Figure 25. Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Pharmacogenomics Technology (Theranostics & CDx) Market Share in 2022
Figure 27. Global Top 6 Players Pharmacogenomics Technology (Theranostics & CDx) Market Share in 2022
Figure 28. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Share by Type (2018-2023)
Figure 29. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Type (2024-2029)
Figure 30. Global Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Share by Application (2018-2023)
Figure 31. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Application (2024-2029)
Figure 32. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 42. France Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Region (2018-2029)
Figure 49. China Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 52. India Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Pharmacogenomics Technology (Theranostics & CDx) Consumption Value (2018-2029) & (USD Million)
Figure 66. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Figure 67. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Figure 68. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Pharmacogenomics Technology (Theranostics & CDx) in 2022
Figure 71. Manufacturing Process Analysis of Pharmacogenomics Technology (Theranostics & CDx)
Figure 72. Pharmacogenomics Technology (Theranostics & CDx) Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
